Saini Setua
University of Tennessee Health Science Center
CancerInternal medicineOncologymicroRNANanotechnologySuppressorMucinNanocarriersChemistryIn vitroImmunologyImmunohistochemistryMicrovesiclesIn vivoTumor microenvironmentChemotherapyPaclitaxelCyclin B1PancaMetastasisDrug deliveryDrugPancreatic cancerGemcitabineExosomeCell cycleCancer researchTransfectionCell growthClinical significanceMedicineBiologyMagnetic nanoparticlesCancer cell
25Publications
7H-index
203Citations
Publications 25
Newest
#1Advait B. Shetty (UTHSC: University of Tennessee Health Science Center)H-Index: 3
#2Prashanth K.B. Nagesh (University of Texas at Austin)H-Index: 10
Last. Subhash C. Chauhan (University of Texas at Austin)H-Index: 49
view all 7 authors...
Pancreatic cancer (PanCa) is a highly lethal disease with a poor 5 year survival rate, less than 7%. It has a dismal prognosis, and more than 50% of cases are detected at an advanced and metastatic stage. Gemcitabine (GEM) is a gold standard chemotherapy used for PanCa treatment. However, GEM-acquired resistance in cancer cells is considered as a major setback for its continued clinical implementation. This phenomenon is evidently linked to de novo lipid synthesis. PanCa cells rely on de novo li...
Source
#1Vivek K. Kashyap (UTHSC: University of Tennessee Health Science Center)H-Index: 8
#1Vivek Kumar Kashyap (UTHSC: University of Tennessee Health Science Center)H-Index: 1
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 5
view all 14 authors...
Abstract In this study, we investigated the therapeutic efficacy of VERU-111 in vitro and in vivo model systems of cervical cancer. VERU-111 treatment inhibited cell proliferation and, clonogenic potential, induce accumulation of p53 and down regulated the expression of HPV E6/E7 expression in cervical cancer cells. In addition, VERU-111 treatment also decreased the expression of phosphorylation of Jak2 (TyR1007/1008) and STAT3 at Tyr705 and Ser727. VERU-111 treatment arrested cell cycle in the ...
2 CitationsSource
#1Kamalika Samanta (UTHSC: University of Tennessee Health Science Center)H-Index: 2
#2Saini Setua (UTHSC: University of Tennessee Health Science Center)H-Index: 7
Last. Subhash C. Chauhan (University of Texas at Austin)H-Index: 5
view all 6 authors...
Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemothe...
19 CitationsSource
#1Andrew E. Massey (UT: University of Tennessee)H-Index: 4
#2Mohammed Sikander (UT: University of Tennessee)H-Index: 7
Last. Subhash C. Chauhan (UT: University of Tennessee)H-Index: 49
view all 13 authors...
Abstract Pancreatic cancer (PanCa) is a major cause of cancer-related death due to limited therapeutic options. As pancreatic tumors are highly desmoplastic, they prevent appropriate uptake of therapeutic payloads. Thus, our objective is to develop a next-generation nanoparticle system for treating PanCa. We generated a multi-layered Pluronic F127 and polyvinyl alcohol stabilized and poly-L-lysine coated paclitaxel loaded poly(lactic-co-glycolic acid) nanoparticle formulation (PPNPs). This formu...
4 CitationsSource
#1Nirnoy Dan (UTHSC: University of Tennessee Health Science Center)H-Index: 6
#2Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 9 authors...
Background: Although, surgical resection and chemotherapy are the gold standard for treating pancreatic cancer (PanCa), poor patient survival remains the problem. Despite being one of the most common oncogenes in human cancer, to date, no success has been achieved to inhibit KRAS. Targeting KRAS has been shown to synergize anti-cancer activity of gemcitabine in pancreatic cancer. Herein, we have developed a supermagnetic iron oxide (SP) nanoparticles for the sustained delivery of KRAS siRNA to t...
Source
#1Kamalika SamantaH-Index: 2
#2Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
Last. Subhash Chandra Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 1
view all 8 authors...
Background-Pancreatic cancer (PanCa) is the third deadliest cancer in United States with a poor survival rate. Despite extensive research efforts, there is no substantial progress in cancer therapeutics due to barrier against intracellular drug delivery. Our group has previously identified that microRNA-145 (miR-145) is downregulated in PanCa, the restoration of which inhibits tumor growth and enhances gemcitabine sensitivity. However, lack of an effective tumor-specific delivery system remains ...
Source
#1Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
#2Saini Setua (UTHSC: University of Tennessee Health Science Center)H-Index: 7
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 14 authors...
Abstract Pancreatic cancer is a complex disease accounting for fibrotic tumors and an aggressive phenotype. Gemcitabine (GEM) is used as a standard therapy, which develops chemoresistance leading to poor patient outcome. We have recently developed a superparamagnetic iron oxide nanoparticle (SPION) formulation of curcumin (SP-CUR), which is a nontoxic, bioactive anti-inflammatory/anti-cancer agent for its enhanced delivery in tumors. In this study, we demonstrate that SP-CUR effectively delivers...
24 CitationsSource
#1Saini SetuaH-Index: 7
#2Sheema KhanH-Index: 23
Last. Subhash C. ChauhanH-Index: 49
view all 8 authors...
Source
#1Vivek K. Kashyap (UTHSC: University of Tennessee Health Science Center)H-Index: 8
#2Qinghui Wang (UTHSC: University of Tennessee Health Science Center)H-Index: 9
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 13 authors...
The management of pancreatic cancer (PanCa) is exceptionally difficult due to poor response to available therapeutic modalities. Tubulins play a major role in cell dynamics, thus are important molecular targets for cancer therapy. Among various tubulins, βIII and βIV-tubulin isoforms have been primarily implicated in PanCa progression, metastasis and chemo-resistance. However, specific inhibitors of these isoforms that have potent anti-cancer activity with low toxicity are not readily available....
11 CitationsSource
#1Sheema Khan (UT: University of Tennessee)H-Index: 4
#2Kyle Doxtater (UT: University of Tennessee)
Last. Meena Jaggi (UT: University of Tennessee)H-Index: 36
view all 10 authors...
Objective: Pancreatic cancer (PanCa) is the third leading cause of cancer-related deaths in the U.S. MUC13, mucin, is aberrantly expressed in PanCa and its overexpression leads to tumorigenic and metastatic behavior of cancer cells. Herein, we investigate the role of MUC13 in tumor microenvironment (TME) that favors PanCa progression/metastasis and drug resistance. Methods: MUC13 expressing (Panc-1) and knockdown PanCa cells (HPAF-II) and pancreatic stromal cells (PSCs), derived from freshly col...
Source